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Abstract
We investigated the therapeutic potential of human bone marrow-derived mesenchymal stem cells (hBM-MSCs) in
Huntington’s disease (HD) mouse models. Ten weeks after intrastriatal injection of quinolinic acid (QA), mice that received
hBM-MSC transplantation showed a significant reduction in motor function impairment and increased survival rate.
Transplanted hBM-MSCs were capable of survival, and inducing neural proliferation and differentiation in the QA-lesioned
striatum. In addition, the transplanted hBM-MSCs induced microglia, neuroblasts and bone marrow-derived cells to migrate
into the QA-lesioned region. Similar results were obtained in R6/2-J2, a genetically-modified animal model of HD, except for
the improvement of motor function. After hBM-MSC transplantation, the transplanted hBM-MSCs may integrate with the
host cells and increase the levels of laminin, Von Willebrand Factor (VWF), stromal cell-derived factor-1 (SDF-1), and the SDF-
1 receptor Cxcr4. The p-Erk1/2 expression was increased while Bax and caspase-3 levels were decreased after hBM-MSC
transplantation suggesting that the reduced level of apoptosis after hBM-MSC transplantation was of benefit to the QA-
lesioned mice. Our data suggest that hBM-MSCs have neural differentiation improvement potential, neurotrophic support
capability and an anti-apoptotic effect, and may be a feasible candidate for HD therapy.
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Introduction
Huntington’s disease (HD) is an autosomal dominant inherited
neurodegenerative disorder for which there is currently no
effective treatment. It is caused by an unstable expansion mutation
of a naturally occurring trinucleotide (CAG) repeat in exon 1 of
the IT15 gene on chromosome 4p16.3 that encodes a ubiquitously
expressed 350-kDa protein named huntingtin. The disorder is
characterized by intellectual decline, movement disorders and
behavioral changes [1,2] that lead to severe debilitation and death,
usually within 15–20 years. The neuropathological changes in HD
are selective and progressive degeneration of striatal GABAergic
medium spiny projection neurons [3] accounts for most of the
clinical features. Currently, there is no proven medical therapy to
alleviate the onset or progression of Huntington’s disease [4].
The clinical uses of cell replacement therapy in neurodegener-
ative diseases have been investigated for the last 20 years.
Although the procedures are theoretically feasible, some limita-
tions of the therapy still give cause for concern. The transplan-
tation of fetal striatal tissue to the striatum to modify HD
progression in humans has been investigated, and some favorable
effects have been found [5,6]. Transplanted fetal neurons can lead
to functional benefit and repair [5], and the transplanted cells
remain viable in the human neostriatum for long periods of time
[6]. However, there are still many unsolved difficulties associated
with the transplantation of human fetal striatal tissue for therapy in
HD such as ethical arguments, viability of tissue source, limitations
on tissue acceptance, the high risk of rejection and concerns about
contamination and heterogeneity of the tissues [7].
The use of renewable and expandable bone marrow-derived
mesenchymal stem cells (BM-MSCs) circumvents many of the
practical and ethical problems associated with the use of human
fetal tissue. BM-MSCs are easy to acquire, have self-renewing
properties, expand rapidly, and may differentiate into all of the
major cell types in the central nervous system [8]. BM-MSCs can
also be harvested directly from patients, with the resulting
autologous transplants avoiding the risk of immune rejection [9].
Transplanted BM-MSCs have a reduced risk of tumor formation
and are able to differentiate into neuronal or glial lineages and
provide functional improvement in the central nervous systems
(CNS) of rodents with Parkinson’s disease [10] and other
neurodegenerative disorders [11,12]. We and others have
demonstrated that intracerebrally transplanted bone marrow-
derived stem cells can migrate to damaged brain areas and
improve neuronal function and architecture in stroke animal
models [8,13]. Furthermore, the function of neurogenic effects of
human multipotent stromal cells (hMSCs) in HD mouse models
had been demonstrated [14]. Therefore, MSCs may provide an
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e22924alternative cell source for transplantation therapy in HD; however,
the possible mechanisms involving in MSCs transplantation are
still unclear. In this study, we demonstrated that hBM-MSC
transplantation may have beneficial effects by increasing neuro-
genesis, attracting neural stem-cell migration, enhancing SDF-1
expression, and decreasing apoptosis in mouse models of HD.
Results
hBM-MSCs May Differentiate and Survive in C57/B6 Mice
First, we investigated whether hBM-MSCs expressed neuronal
markers in vitro. Our results showed that GFAP (a marker for
astrocytes), NeuN (a marker for neurons), and DARPP-32 (a
marker of striatal medium-sized spiny projection neurons) were all
not detected in the hBM-MSCs before transplantation into mouse
striata.
Next, we investigated the fate of hBM-MSCs after transplan-
tation in C57/B6 mice. We used bisbenzimide labeling [15] and
immunofluorescence with cell type-specific markers to trace and
determine the cell types of differentiated hBM-MSCs in the
striatum of C57/B6 mice. Eight weeks after hBM-MSC
transplantation, confocal microscope images showed some bis-
benzimide-labeled cells co-expressing GFAP (Fig. 1A; a–d), NeuN
(Fig. 1B; a–d), and DARPP-32 (Fig. 1C; a–d) throughout the
transplantation region in the striatum. We also used TOTO3 dye
(Fig. 1; A-c, B-c & C-c) to confirm the positions of cell nuclei, and
found the TOTO3 signal in many cells was colocalized with the
bisbenzimide signal, demonstrating the differentiation of hBM-
MSCs after transplantation. Such cell differentiation was not
obvious in the sham-control group (Fig. 1; A-e, B-e & C-e).
Tumorigenesis is an important consideration in stem cell
transplantation. To investigate the tumorgenetic potential of
hBM-MSCs, we transplanted hBM-MSCs into the striatum of
C57/B6 mice and followed them for at least 17 months. Seventeen
months after hBM-MSC transplantation, there was no turmor-
igenesis in the surgical region as assessed by hematoxylin and eosin
staining (Fig. 1D). These results suggest that hBM-MSCs could
survive and differentiate successfully within the transplanted
mouse striatum.
hBM-MSC Transplantation Improves Striatum Volume,
Rotarod Performance, and Survival Rates after QA-
induced Excitotoxicity
We used the QA-lesioned mouse model to evaluate the effects of
hBM-MSC transplantation. Ten weeks after surgery, striatum
volumes were not changed in the sham-control mice (Fig. 2A; a),
but were obviously decreased in the QA-lesioned (Fig. 2A; b) and
QA+transplant groups (Fig. 2A; c). However, striatum volumes in
QA+transplant group were partially recovered in comparison with
QA-lesioned group (Fig. 2A; d). The striatum volume of the wild-
type sham-control was approximately 6.3 mm
3, while in the
QA2lesioned and QA+transplant groups striatum volume was
2.0 mm
3 and 2.7 mm
3, respectively. We then used rotarod
performance as an indicator of motor function in mice to estimate
the effects of hBM-MSCs. One week after QA lesioning, both the
QA2lesioned and QA+transplant groups showed an obvious
reduction in rotarod performance compared to normal mice. The
motor function of the QA+transplant group recovered more
rapidly than the QA2lesioned group and was significantly
different from 10 weeks until at least 13 weeks (Fig. 2B) after
transplantation. The survival rate of the QA+transplant mice
during the 10 weeks after QA lesioning was significantly higher
than that of the QA2lesioned mice (Fig. 2C), suggesting that
hBM-MSC transplantation could elicit behavioral and survival
recovery after QA lesioning.
hBM-MSCs Improve Cell Proliferation and Differentiation
after Transplantation in QA2lesioned Mice
To monitor the effects of hBM-MSCs after transplantation,
experimental mice were injected subcutaneously with BrdU
(50 mg/kg) once-a-day for 7 days before being sacrificed at
different time-points. Sixteen weeks after QA lesioning, BrdU-
immunoreactive cells were rarely detected in the sham-control
(Fig. 3A; a) and few were detected in the QA2lesioned mice
(Fig. 3A; b); however, BrdU-immunoreactive cells were abundant
in the QA+transplant group (Fig. 3A; c). The quantitative results
clearly show a significantly higher number of BrdU-immunoreac-
tive cells in the QA+transplant group than in sham-control and the
QA2lesioned groups (Fig. 3A; d). In addition, the phenomenon of
cell proliferation could last for at least 16 weeks after QA lesioning
(data not shown), which revealed that hBM-MSC transplantation
increased cell proliferation in the striatum region of QA+trans-
plant mice.
Next, we determined the cell types and numbers of differenti-
ated hBM-MSCs surviving in the QA impaired striatum using the
same approach as used above with the C57/B6 mice. Eight weeks
after hBM-MSC transplantation, confocal microscope images
showed a small number of bisbenzimide-labeled cells in the
QA2lesioned striatum co-expressing DARPP-32 (Fig. 3B; a–d).
Furthermore, more GFAP- or NeuN-expressing cells (Fig. 3C; a–
d) were seen throughout the QA impaired striatum, and a large
number of GFAP-expressing cells which were not colocalized with
the bisbenzimide signals surrounded the core of the QA lesion. In
addition, many cells expressing F4/80 (a marker for microglia)
were found near the GFAP-expressing cells (Fig. 3D; a–d). Such
cell differentiation and proliferation was seldom detected in the
QA2lesioned group (Fig. 3; B-e, C-e & D-e). The quantitative
results show a significantly higher number of DARPP-32, NeuN,
GFAP, and F4/80 positive cells in the QA+transplant group than
in the QA2lesioned group (Fig. 3E).
To demonstrate that the transplanted hBM-MSCs were actually
alive, we used an anti-human mitochondria antibody to trace the
hBM-MSCs. We observed that cells with positive signals were
colocalized with GFAP positive cells (Fig. 3F; a–e). A small amount
of cells with human mitochondria marker were sustained for 16
weeks in the QA+transplant group (Fig. 3G; a–d), indicating that
hBM-MSCs could survive in vivo for a long period of time. There
was no cell with human mitochondria marker detected in the
QA2lesioned group (Fig. 3G; e). These findings suggest that some
transplanted hBM-MSCs could survive and differentiate into
astrocytes and neurons. In addition, some astrocytes encircled the
core of the QA2impaired region and the hBM-MSCs attracted
microglia nearby. This suggests that hBM-MSCs may differentiate
differently and increase the neurogenesis within the QA2impaired
striatum.
hBM-MSCs Improve Survival Rates and Cell
Differentiation after Transplantation into R6/2-J2 HD
Mice
In order to prove the universal therapeutic potential of hBM-
MSCs, a genetically-modified HD rodent model R6/2-J2 was used
to investigate the neuroprotective function of hBM-MSCs. Sixteen
weeks after surgery, both hBM-MSC-transplant and PBS-control
groups showed obvious reduction in rotarod performance
compared to the normal mice, but there were no significant
differences between hBM-MSC-transplant and PBS-control
Trophic Support of hBM-MSCs in HD Mouse Models
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in striatum volumes between the two HD groups (data not shown);
this was perhaps because the extent of striatal atrophy in R6/2-J2
mice was not obvious. These results were not consistent with the
effect observed in QA mice and revealed that the severe atrophy in
R6/2-J2 mouse muscles could not be rescued efficiently by the
transplanted hBM-MSCs in the brain. Although the PBS-control
R6/2-J2 mice and the hBM-MSC-transplant R6/2-J2 mice could
not survive beyond 32 and 36 weeks of age, respectively, the
median survival age of PBS-control (30.5 weeks) and hBM-MSC-
transplant R6/2-J2 mice (33 weeks) were significantly different
(Fig. 4B). Further investigation of the effects of transplanted hBM-
MSCs in the R6/2-J2 mice suggested a similar result to that shown
in C57/B6 mice. A portion of the bisbenzimide-labeled cells
identified in the striatum of the R6/2-J2 mice retained DARPP-32
expression (Fig. 4C; a–d). Moreover, some of the transplanted
hBM-MSCs also emitted intense GFAP signals (Fig. 4D; a–d)
throughout the transplanted striatum of R6/2-J2 mice. Some F4/
80-expressing cells close to the GFAP-expressing cells were also
observed (Fig. 4E; a–d). Such cell differentiation was seldom
detected in the PBS-control R6/2-J2 mice (Fig. 4; C-e, D-e & E-e).
The quantitative results show a significantly higher number of
DARPP-32, GFAP, and F4/80-positive cells in the hBM-MSC-
transplant group than in PBS-control R6/2-J2 mice (Fig. 4F).
These findings suggest that hBM-MSCs could improve animal
survival and cell differentiation not only in the QA-induced mouse
model but also in the genetic model of HD.
Transplanted hBM-MSCs Play a Trophic Role in the HD
Mouse Model
Although only a minority of hBM-MSCs differentiated and
expressed different cell markers, including GFAP, NeuN, and
DARPP-32, the improvement in survival rate in hBM-MSC
transplant mice was significant. We were therefore interested in
whether the therapeutic potential of hBM-MSCs was caused by
trophic support. Thus, bone marrow replacement mice were used
to investigate whether the hBM-MSCs attracted cells from other
sources into the striatal regions in QA2lesioned mice. The
replacement bone marrow cells were GFP-labeled to distinguish
whether the cells attracted by hBM-MSCs came from peripheral
blood. After bone marrow replacement, mice underwent QA
lesioning and hBM-MSC transplantation as previously described.
Figure 1. Transplanted hBM-MSCs differentiated and survived in wild-type C57/B6 mice. (A–C) Confocal laser microscopic analysis of
immunofluorescence labeled striatal sections in hBM-MSCs transplanted wild-type C57/B6 mice, 8 weeks after striatal transplantation with hBM-MSCs.
Transplanted hBM-MSCs pre-labeled with bisbenzimide (b; blue) or labeled with TOTO3 (c; white) were immunostained against various cell markers,
including GFAP (A-a; green), NeuN (B-a; red), and DARPP-32 (C-a; red). Corresponding merged images are shown accordingly (d). Images from the
sham-control group (e) are stained with the same cell markers as hBM-MSC-transplant group (d). Scale bar=10 mm. (D) After 17 months, hematoxylin
and eosin staining of brain transplanted with hBM-MSCs showed no turmorigenesis in the transplantation region (yellow dotted line demarcates the
involved region). Scale bar=20 mm.
doi:10.1371/journal.pone.0022924.g001
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derived BM cells had GFP signals eight weeks after BM
replacement (Fig. 5A, a–d), and some GFP-expressing neuron–
like cells appeared in the striatum (Fig. 5B&C, a–d). Additionally,
neuron-like cells were seen in the striatal region, but these neuron-
like cells were only found near neuroblasts (marked by Dcx,
Fig. 5B; a–d) or neurons (Fig. 5C; a–d) and did not differentiate
into these cell-types. In addition, only about 40 GFP-positive cells
were identified in the hemispheres of striata of bone marrow-
replaced QA2lesioned mice. These results suggest that only a few
endogenous bone marrow-derived cells may be attracted by hBM-
MSCs to the impaired striatum in QA+transplant mice.
hBM-MSC Transplantation Induces Migration of
Neuroblast Cells in HD Mouse Models
Most GFAP and F4/80 expression was not colocalized with
bisbenzimide signals, as described above, so we presumed that the
bisbenzimide-unlabeled cells came from the source other than the
QA2damaged cells. Having established that after neuronal injury,
neural stem cells could replace the dead cells in the brain, we tried
to find out whether the bisbenzimide-unlabeled cells were
originally endogenous neural stem cells. We found intense staining
by Dcx antibody (a marker for mouse neuroblasts) in the
QA+transplant group (Fig. 5D; a–d) and R6/2-J2+transplant
group (Fig. 5E; a–d). The Dcx-immunoreactive cells were all
bisbenzimide-negative cells located close to bisbenzimide-labeled
cells which coexpressed NeuN or GFAP. This phenomenon was
much less apparent in the PBS-control groups (Fig. 5; D-e & E-e),
as shown in the quantitative results (Fig. 5F). Fig. 5 B and C
demonstrate that in both the QA-lesioned and genetically-
damaged striatum, hBM-MSCs had a trophic effect, and the
BM is one of the regions that is affected by the trophic effect. In a
previous study, implantation of human MSCs stimulated prolif-
eration, migration, and differentiation of the endogenous neural
stem cells within the hippocampus [16]. We hypothesize that GFP
negative cells from other sources such as neural stem cells, were
attracted by hBM-MSCs in BM replacement mice as shown in
Fig. 5 D and E.
Figure 2. Transplanted hBM-MSCs improved striatal volumes, motor function, and survival rates in QA2lesioned mice. (A)
Photomicrographs show the difference in striatal volumes in unilateral lesion mice. There was no striatal atrophy in the sham-control group (a), but
the striatal volumes in the lesion side of QA2lesioned (b) and QA+hBM-MSC-transplant (c) groups were significantly decreased compared with the
contralateral side. Arrows indicate surgery sites in each group. Scale bar=400 mm. (d) Quantification of striatal volumes show increased volumes in
the QA+hBM-MSC-transplant group. (B) Rotarod performance of mice was tested over 2 min duration at 30 r.p.m. Sham-control mice exhibited
normal motor function, but QA2lesioned and QA+transplant groups showed decreased motor function at 1, 10, and 13 weeks after QA lesioning. Ten
and 13 weeks after QA lesioning, the QA+transplant group exhibited better motor function than the QA2lesioned group. (C) Survival rates after QA
lesioning. Twenty-four mice were all alive in the sham-control group, whereas 9/24 mice (37.5%) were alive in the QA2lesioned group and 16/24
(66.7%) were alive in the QA+transplant group 10 weeks after surgery. Error bars represent SD, and *P,0.05, ** P,0.001, *** P,0.0001.
doi:10.1371/journal.pone.0022924.g002
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PLoS ONE | www.plosone.org 4 August 2011 | Volume 6 | Issue 8 | e22924Figure 3. Transplanted hBM-MSCs improved cell proliferation and differentiation in QA2lesioned mice. (A) Photomicrographs showing
the presence of BrdU-labeled cells throughout the transplanted hemisphere. Only rare BrdU signals were detected in the sham-control group (a) and
the QA2lesioned group (b), but many BrdU-labeled cells (dark brown) were observed in the QA+hBM-MSC-transplant striatum (c) 10 weeks after
transplantation. Scale bar=50 mm. (d) Quantification of BrdU-labeled cells showed numerous BrdU-labeled cells in the QA+hBM-MSC-transplant
group. (B–D) Confocal laser microscopic analysis of immunofluorescence labeled striatal sections in QA2lesioned and hBM-MSCs transplanted mice, 8
weeks after a striatal lesioning with QA. Transplanted hBM-MSCs pre-labeled with bisbenzimide (c; blue) were immunostained against cell markers
Trophic Support of hBM-MSCs in HD Mouse Models
PLoS ONE | www.plosone.org 5 August 2011 | Volume 6 | Issue 8 | e22924Transplanted hBM-MSCs Might Integrate with Host Cells
and Improve Angiogenic Activity in the Damaged Striatal
Region
It has been reported that the raised expression of synaptic
marker proteins, including the presynaptic vesicle protein,
synaptophysin, is evidence of synapse formation [17,18]. Our
examination showed that synaptophysin expression was coloca-
lized with bisbenzimide-labeled cells (Fig. 6A, a–d). In addition, we
also observed that some synaptophysin signals did not colocalize
with the bisbenzimide-labeled signals but rather surrounded
bisbenzimide-labeled cells (Fig. 6A, a–d) which was seldom
detected in the QA-lesioned group (Fig. 6A; e), revealing that
hBM-MSCs have the potential to form synapses and might
integrate with the host cells.
Since angiogenesis is a prerequisite for tissue reconstitution,
hBM-MSCs may improve angiogenesis as they attract neural stem
cells and bone marrow-derived cells to migrate to the striatum.
Laminin, an extracellular matrix (ECM) marker used to identify
the formation of new blood vessels [19] was used here as a marker
for angiogenic activity. After hBM-MSC transplantation, intense
laminin expression was seen near the hBM-MSC injection region,
close to Dcx-expressing areas (Fig. 6B; a–d) but expression was
much less in the QA2lesioned group (Fig. 6B; e).
Although the neurogenic effects of hMSCs by increasing
neurotrophin signaling have been demonstrated [14], we expected
that hBM-MSCs may also exert benefical effects through other
pathways. SDF-1 is an indispensable chemoattractant for neuron
migration in different brain regions [20]. Laminin is an important
ECM that enhances the chemotactic activity of SDF-1 in the
thymus [21]. We thus investigated the relationship between
laminin and SDF-1 in our QA-lesioned HD mouse model. We
did indeed find numerous SDF-1 signals adjacent to the regions of
increased laminin expression (Fig. 6C; a–d) around the hBM-MSC
injection site, but again, significantly less in the QA2lesioned
group (Fig. 6C; e).
We also used the endothelium marker VWF to verify the
angiogenic activity after hBM-MSC transplantation. There were
intense VWF expression signals in the QA injection region, close
to the bisbenzimide-labeled cells, in the transplant group (Fig. 6D;
a–c), but not in the QA2lesioned group (Fig. 6D; d). Thus, hBM-
MSCs appear to play a trophic role, inducing Dcx and SDF-1
expression in the striatum of transplant mice to improve
angiogenesis.
Because the SDF-1 expression was raised after hBM-MSC
transplantation, we investigated the expression of the SDF-1
receptor Cxcr4 around the surgical regions. Immunofluorescence
staining results show more intense Cxcr4 expression signals
around the bisbenzimide-labeled cells in the QA+transplant group
(Fig. 6E; a–d) than in the QA2lesioned group (Fig. 6E; e). The
quantitative results of the immunofluorescence staining show the
numbers of laminin-, Dcx- and Cxcr4-positive cells (Fig. 6F), and
the expression areas of SDF-1 (Fig. 6G) and VWF (Fig. 6H) are
significantly higher in the QA+transplant group than in the
QA2lesioned group. Thus, hBM-MSCs may minimize QA
damage through stimulating SDF-1 and Cxcr4 expression.
To further quantify RNA expression after hBM-MSC trans-
plantation, we used qRT-PCR to identify the levels of SDF-1 and
Cxcr4. In the QA mouse model 8 weeks after hBM-MSC
transplantation, the expression levels of Cxcr4 were increased but
the levels of SDF-1 were not significantly different from the non-
transplant group (Fig. 7A). Moreover, in the R6/2-J2 mouse
model, one week after hBM-MSC transplantation, the expression
levels of SDF-1 and Cxcr4 were upregulated (Fig. 7B). These
results were similar to the data from immunohistochemical
analysis.
Transplanted hBM-MSCs Reduce Apoptosis after
Transplantation in QA2lesioned Mice
SDF-1 is constitutively expressed in many tissues and has been
demonstrated to significantly inhibit serum depletion-induced
apoptosis [22] and downregulate caspase-3 cleavage [23]. We
assayed caspase-3 and TUNEL to measure apoptosis after hBM-
MSC transplantation, and found that hBM-MSCs decreased both
caspase-3 expression (Fig. 8A; a–c) and the level of fragmented
DNA (Fig. 8B; a-c) more than in QA2lesioned group without
transplantation (Fig. 8; A-d & B-d).
There are many factors involved in apoptotic regulation. In
particular, p-Erk1/2 and Bax are two factors that can be
modulated by SDF-1 [22,24]. We found that p-Erk1/2 expression
was increased (Fig. 8C; a) and the number of Bax-positive cells was
decreased (Fig. 8C; b) in the QA+transplant group (Fig. 8C; a–e)
compared to the QA2lesioned group (Fig. 8D; a–e). Both p-Erk1/
2 upregulation and Bax downregulation are beneficial in reducing
apoptosis. The quantitative results show a significantly lower
number of caspase-3, TUNEL, and Bax-positive cells but higher
number of p-Erk1/2-positive cells in the QA+transplant group
than in QA2lesioned group (Fig. 8E). We thus suggest that hBM-
MSCs may diminish the amount of apoptosis through regulation
of the expression of p-Erk1/2 and Bax.
Discussion
In the present study, we investigated whether hBM-MSCs can
survive, differentiate, and integrate into the striatum after
transplantation, and thereby reduce ongoing striatal damage and
improve functional recovery in QA2lesioned or genetically-
modified HD mouse models. Transplantation of hBM-MSCs
reduced motor dysfunction in striatal QA2lesioned mice, as
determined by rotarod performance. Within the damaged
striatum, a few hBM-MSCs underwent differentiation, as shown
by the expression markers for striatal medium spiny projection
neurons, mature neurons and astrocytes; and moreover, the stem
cells induced microglia and neuroblasts to migrate to the damaged
striatal region. These observations were all reproduced in the R6/
2-J2 mouse model, except for the amelioration in motor
dysfunction. Furthermore, endogenous bone marrow-derived cells
DARPP-32 (B-a; green), NeuN (B-b & C-b; red), GFAP (C-a; green & D-b; red), and F4/80 (D-a; green). Corresponding merged images are shown
accordingly (d). Images from the QA2lesioned group (e) are stained with the same cell markers as QA+transplant group (d) except that the
bisbenzimide labeling was substituted with DAPI staining. Arrows indicate colocalization of hBM-MSCs and cell markers, white for DARPP32, pink for
GFAP, and yellow for NeuN. Scale bar=10 mm. (E) Quantitation of DARPP-32, NeuN, GFAP, and F4/80-positive cells in the hemispheres of striata from
QA+transplant and QA2lesioned groups. Error bars represent SD, and ** P,0.001, *** P,0.0001. (F–G) Confocal laser microscopic analysis of
immunofluorescence labeled striatal sections in QA2lesioned and hBM-MSC transplant mice, 8 weeks (F) and 16 weeks (G) after a striatal lesioning
with QA. Transplanted hBM-MSCs pre-labeled with bisbenzimide (b; blue) and co-labeled with TOTO3 (c; white) were immunostained against human
mitochondria marker (a; green) or GFAP (d; red). Corresponding merged images are shown accordingly (F-e & G-d). Images from the QA-lesioned
group (G-e) are stained with the same cell markers as QA+transplant group (G-d). Arrows show the colocalization of hBM-MSCs and cell markers. Scale
bar=10 mm.
doi:10.1371/journal.pone.0022924.g003
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PLoS ONE | www.plosone.org 6 August 2011 | Volume 6 | Issue 8 | e22924Figure 4. Transplanted hBM-MSCs improved animal survival rate and cell differentiation in R6/2-J2 mice. (A) Rotarod performance of
mice after treatment. Compared to the normal motor function exhibited by the wild-type sham-control mice, both the hBM-MSC-transplant and PBS-
control R6/2-J2 mice showed significant reduction in latency during the rotarod task. No improvement in motor function was identified in the hBM-
MSC-transplant group compared with the PBS-control R6/2-J2 mice at 28 weeks of age. (B) Survival rates of animals after hBM-MSC transplantation.
All the wild-type sham-control mice (n=12) were alive at 36 weeks; whereas, the PBS-control R6/2-J2 mice (n=10) and the hBM-MSC-transplant R6/2-
J2 mice (n=11) were all died by 32 and 36 weeks of age, respectively. The median survival of PBS-control and hBM-MSC-transplant R6/2-J2 mice were
30.5 and 33 weeks old, respectively, and there was a significant difference between the groups. (C–E) Confocal laser microscope observation of
immunofluorescence labeled striatal sections in R6/2-J2 mice, 12 weeks after hBM-MSC transplantation. Transplanted hBM-MSCs pre-labeled with
Trophic Support of hBM-MSCs in HD Mouse Models
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QA2lesioned region. The levels of the angiogenesis markers
laminin and VWF and of the chemokine SDF-1 near the hBM-
MSCs were all elevated. Together, these results indicate that
transplanted hBM-MSCs may alleviate cell damage in the HD
mouse model through three possible mechanisms: (A) neuronal
differentiation, (B) chemokine secretion, and (C) proliferation
induction (See the schematic representation in Fig. 9).
Mesenchymal stem cells (MSCs) are a distinguishable popula-
tion of cells that are able to differentiate into bone, cartilage, and
other tissues [25], and can be easily obtained and autotransplant-
ed. Therefore, MSCs have great potential for clinical application.
In addition, these cells are not thought to induce strong
immunoresponses in recipients [26], and their potential use in
therapy for neurodegenerative diseases, such as HD, has been
reported [27,28]. The chemotactic signals and homing capabilities
of MSCs are well-proven [29], but the particular mechanisms and
molecules involved are still unclear. Some recent studies focusing
on the transplantation of MSCs in different HD models have
highlighted the potential of MSCs in the amelioration of striatal
degeneration [30] and improving behavioral abnormalities in
QA2lesioned rats [31]. Furthermore, MSC-transplantation com-
bined with neurotrophic factor secretion showed therapeutic
effects in different HD models [28,32]. Moreover, the function of
MSCs in providing trophic support has been demonstrated in a
Parkinson’s disease model [33]. Therefore, we tried to investigate
the details of hBM-MSC application in HD therapy using QA and
transgenic mouse models.
The excitotoxicity generated by QA has been demonstrated to
induce the degeneration of striatal neurons, with a specific loss of
GABAergic neurons [34], and to cause similar abnormalities in
motor, emotional, and cognitive functions that appear in HD patients
[35]. The QA2lesioned rat model had been used extensively in
studies ofcelltherapy [27,28,30,36], but QA2lesioned mousemodels
are rare [14,37]. The application of MSCs to HD transgenic mice
has, however, been proved beneficial in increasing neurotrophic
factor expression in HD mice [14]. We thus included the QA mouse
model as one of our therapeutic targets in our investigations of the
possible mechanisms involved in MSC transplantation. On the other
hand, the use of a transgenic mouse model such as R6/2-J2
demonstrated the feasibility of application of this research in HD
patients with a genome bearing a CAG repeat-expanded huntingtin
allele. Early death and lack of neuronal degeneration make the use of
R6/2 mice difficult in cell transplantation studies, and we therefore
used R6/2-J2 mice, which die around 32–36 weeks of age, as the
therapeutic target to provide a longer period for evaluation of
functional improvement after cell transplantation.
Astrocyte populations in different brain regions have been
shown to have important roles in neurogenic support [38]. In HD
brains, mutant huntingtin reduces glial glutamate uptake and this
dysfunction may be associated with neuronal excitotoxicity [39].
Moreover, mutant huntingtin may affect the production of
chemokines such as tumor necrosis factor alpha (TNF-a) [40]
and neurotrophic factors such as glial-derived neurotrophic factor
(GDNF) [41] and nerve growth factor (NGF) [42] from glial cells.
In our experiments, the small number of hBM-MSCs that
differentiated into glial cells may contribute to chemokine
secretion and hBM-MSC transplantation may provide a beneficial
environment that attracts glial cell activation and proliferation
[43]. Once the numbers of activated glial cells are boosted, their
trophic support will slow the excitotoxic damage to GABAergic
neurons in the striatum.
In the injured brain, some upregulated environmental elements
may account for the migration of endogenous neural stem cells or
transplanted immortalized, neonate-derived neural precursor cells
to the lesioned region and their differentiation into neurons
[44,45]. In the present study, brain injury induced neurogenesis
and enhanced neuronal migration to the lesioned region to
enhance proliferation of correct cell types, such as Dcx-expressing
neuroblasts, to reconstruct the damaged cell architecture, as seen
after stroke [46]. It has been demonstrated that Dcx-positive cells
can migrate toward the lesioned striatum from the dorsal region of
the striatum following neuronal environment disruption, such as
from cortical lesions [47], and these cells are in close spatial
relationships with blood vessels. Dcx was considered to be a
marker for new-born neurons [48] which undoubtedly reflects the
number of proliferating cells which were BrdU-positive. In other
HD mouse models such as R6/1 and R6/2, diseased mice had
decreased neurogenesis [48,49]. In our studies, Dcx-positive cells
were induced by hBM-MSC transplantation, resulting in increased
neurogenesis and the recruitment of numerous appropriate cells to
further benefit the damaged cells in the striatum.
Laminin, produced by neurons and astroglia, is important in
regulation of cell behavior in the central nervous system [50] and
vascular remodeling in angiogenesis [19]. Laminin is also important
in axon growth and guidance. The identified stem cell niches, such
as the subventricular zones (SVZ) [51] and bone marrow stroma,
containlaminins[52],thus a close relationshipbetweenlamininand
stem cells is expected. Bone marrow cell transplantation has been
demonstrated to induce angiogenesis [53] and benefit artery disease
[54,55]. Combining these results with our present study, we
hypothesize that hBM-MSCs act as a paracrine stimulator and
improve laminin expression, resulting in angiogenesis. Such
angiogenesis should result in chemokines such as SDF-1 [56],
angiogenic molecules, such as vascular endothelial growth factor
(VEGF) [57], and neurotrophic factors, such as fibroblast growth
factor (FGF), ciliary neurotrophic factor (CNTF), and nerve growth
factor (NGF) [14] having more chance to reach the injured region
through the newly formed blood vessels, thus further benefiting the
damaged neurons, and finally causing the functional improvement
seen in our HD mouse models. SDF-1 activates the Cxcr4 receptor
expressed in several neuronal cells, including microglia, astrocytes
[58],andGABAergicprecursors[20],todirectthemigrationofnew
neurons[59] and promote neuronalprogenitor motility [60] toward
damaged neurons. Once laminin improves blood vessel formation,
SDF-1 may be secreted and moved through the angiogenic areas to
influence neurogenesis.
The mechanisms by which hBM-MSC transplantation benefits
QA2lesioned and genetically-manipulated mouse models of HD
were investigated in this study. BM-MSC downregulation of the
caspase-3-mediated apoptotic pathway in rat spinal cord injury
[61] and SDF-1 regulation of anti-apoptosis in different models
[22,23] have been reported. Our study showed that expression of
SDF-1 was upregulated by hBM-MSCs, which exerted anti-
bisbenzimide (C-b, D-b & E-c; blue) or co-labeled with TOTO3 (C-c & D-c; white) were immunostained against cell markers DARPP-32 (C-a; green),
GFAP (D-a; green & E-b; red), and F4/80 (E-a; green). Corresponding merged images are shown accordingly (d). Images from the PBS-control R6/2-J2
mice (e) were stained with the same cell markers as the hBM-MSC-transplant group (d). Arrows show the colocalization of hBM-MSCs and cell
markers. Scale bar=10 mm. (F) Quantitation of DARPP-32, GFAP, and F4/80-positive cells in the hemispheres of striata from hBM-MSC-transplant and
PBS-control R6/2-J2 groups. Error bars represent SD, and ** P,0.001, *** P,0.0001.
doi:10.1371/journal.pone.0022924.g004
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PLoS ONE | www.plosone.org 8 August 2011 | Volume 6 | Issue 8 | e22924Figure 5. Transplanted hBM-MSCs attract cell migration into the striatum. (A) Confocal laser microscopic observation of cells from mouse
bone marrow 8 weeks after bone marrow replacement. Cells were observed under GFP fluorescence (a; green), DAPI nuclear staining (b; blue) and
DIC (c) conditions, respectively. Merged images are shown accordingly (d). Scale bar=20 mm. (B–C) Confocal laser microscopic observation of
immunofluorescence labeled striatal sections 8 weeks after hBM-MSC transplantation in mice with QA2lesioned and bone marrow replacement.
Bone marrow-derived cells labeled with GFP (a; green) were close to neuroblast cells (B-b; red) or internal neuron cells (C-b; red) in the striatum after
hBM-MSC transplantation. TOTO3 signals (c; blue) represent the cell nuclei in the striatum. Corresponding merged images are shown accordingly (d).
Scale bar=10 mm. (D–E) Confocal laser microscopic observation of immunofluorescence labeled striatal sections in hBM-MSCs transplanted QA-
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Bax, ultimately protecting the QA2lesioned and genetically-
blemished cells. In addition, increased neurogenesis and neuro-
protection by neurotrophic or growth factors, and new synapse
formation with reorganization, have been suggested by stroke
models [62]. The decreased striatal atrophy and the improved
functional recovery of the HD model in our study also suggest that
hBM-MSC transplantation protects the host brain from further
destruction. Our results indicate that, within the impaired
striatum, while these transplanted hBM-MSCs were viable for at
least 120 days after transplantation, only a few transplanted cells
(less than 10% of the transplanted hBM-MSCs) actually
underwent engrafting, differentiating into neurons and glia. This
suggests that transplanted hBM-MSCs at least partially contribute
to improved neurological function through the release of various
molecules rather than through the establishment of a new
neuronal network between the transplanted and the host tissue.
Transplanted cells in the excitotoxic lesion have been described to
exert trophic support by the secretion of different neurotrophic
factors, such as NGF and epidermal growth factor (EGF) [63,64].
Thus, a few of the neurons surviving in the QA2lesioned and
genetically impaired striata or the neurotrophic factors released
from the active astrocytes may provide a suitable environmental
niche for transplanted hBM-MSCs to settle and further differen-
tiate into neurons or in turn release other neurotrophic factors to
induce neurogenesis.
Several clinical studies have used different kinds of tissues as
sources for transplantation into the striatum of HD patients, but
therapeutic results have not always been predictable
[6,65,66,67,68,69]. Only Krystkowiak and Reuter found clinical
improvement, and this occurred over a period of several years
[65,67]. One possible explanation for these results is that severely
damaged tissues surrounding the transplanted cells were unable to
protect against degeneration [69]and there was a lack of
connection between grafts and transplanted areas that blocked
the therapeutic benefits of grafts [67]. In our studies, we found
abundant laminin and VWF expression which could provide
better connections between grafts and neuronal cells in degener-
ating regions which might have benefits in cell transplantation.
We, therefore, believe that hBM-MSCs may have more potential
than the fetal grafts used in previous studies.
In summary, we have demonstrated that hBM-MSCs trans-
planted intrastriatally survive after transplantation in the QA and
genetically impaired striatum, induce functional recovery and
improve neuronal differentiation with a proportion of newly-
generated cells expressing markers characteristic of neurons or
associated cells. Furthermore, we have demonstrated that
transplantation of hBM-MSCs reduces the motor function
impairment observed in the QA2lesioned HD model. The motor
function improvement in this study is promising and lends support
to the hypothesis that some transplanted hBM-MSCs have the
potential to generate functionally mature striatal neurons that
form appropriate graft-host relationships which may restore
impaired striatal circuits. Angiogenesis, chemo-attraction, and
anti-apoptosis may be the major mechanisms provided by hBM-
MSCs. Collectively, this study demonstrates the therapeutic
potential of hBM-MSCs for cell replacement therapy and indicates
that hBM-MSCs may provide an alternative cell source for




Experimental procedures involving animals were approved by
the Animal Care and Use Committee of the Institute of Molecular
Biology, Academia Sinica with permit number RMiIMBLH-
2008041, and all the experimental procedures involving animals
were and performed according to the guidelines established by the
Animal Care and Use Committee of the Institute of Molecular
Biology, Academia Sinica, Taipei, Taiwan. Ninety adult 8- or 12-
week-old male C57/B6 mice weighing 25–30 g (National
Laboratory Animal Center, Taipei, Taiwan) and sixty 12-week-
old male R6/2-J2 mice (The Jackson Laboratory) were used in this
study. R6/2-J2 mice are a R6/2 line with an average of 298 CAG
repeats in a mixed CBA/J and C57BL/6J background. All
animals were randomly housed, five mice per cage, at 21uC and
65% humidity with a 12-h light/dark cycle (lights on at 07:00 am).
Water and food were freely available throughout the study.
Bone Marrow Replacement Mice
Adult 8-week-old male C57/B6 mice were anesthetized with an
intraperitoneal (i.p.) injection of 0.5 g/kg chloral hydrate (Riedel-
de Haen, Seelze, Germany), and received 1200 rad total body c-
irradiation (Mark I Model 68A Irradiator, J.L. Shepherd and
Associates, CA). Twenty-four hours later, c-exposed mice were
transplanted with 3610
6 bone marrow cells obtained from femurs
of 12-week-old GFP transgenic mice by tail vein injection. Eight
weeks later, the bone marrow replacement mice underwent
excitotoxic lesioning.
Cell Culture of hBM-MSCs
Adult hBM-MSCs were kindly provided by Dr. Junya
Toguchida (Kyoto University, Japan). The cells were immortalized
to a cell-line by retrovirus-mediated gene transfer of human
telomerase reverse transcriptase (hTERT) combined with human
papillomavirus E6 and E7 without affecting their potential for
adipogenic, osteogenic, and chondrogenic differentiation. The
cell-line was maintained in DMEM (GibcoBRL) with 10% FBS
(GibcoBRL) and 100 U/ml penicillin/streptomycin (GibcoBRL).
On the day of transplantation, hBM-MSCs were labeled with
bisbenzimide (Bis; 1 mg/ml; Sigma) 10 min before detachment
with trypsin.
Excitotoxic Lesioning and hBM-MSC Transplantation into
Mouse Striatum
Before surgery, 12-week-old male C57/B6 mice were anesthe-
tized (0.5 g/kg chloral hydrate i.p.) and positioned in a stereotaxic
apparatus (Stoelting). All mice received unilateral intrastriatal
injections of 1 ml quinolinic acid (QA) dissolved in 0.1 M
phosphate buffer (PBS) (85 nmole/ml, pH 7.4) via a 10 ml
Hamilton syringe at the following coordinates: AP +0.5 mm,
ML 22.0 mm, and DV 23.0 mm, from the bregma. Seven days
post QA administration mice were randomly divided into two
lesioned mice (D), 8 weeks after striatal transplantation with hBM-MSCs, or R6/2-J2 mice (E), 12 weeks after striatal transplantation with hBM-MSCs.
Transplanted hBM-MSCs pre-labeled with bisbenzimide (c; blue) were immunostained against cell markers, Dcx (a; green) and NeuN (b; red).
Corresponding merged images are shown accordingly (d). Images from the sham-control group (e) were stained with the same cell markers as the
hBM-MSC-transplant group (d). Scale bar=10 mm. (F) Quantitation of Dcx-positive cells in the hemispheres of striata in the QA2lesioned and R6/2-J2
mice. Error bars represent SD, and * P,0.05, *** P,0.0001.
doi:10.1371/journal.pone.0022924.g005
Trophic Support of hBM-MSCs in HD Mouse Models
PLoS ONE | www.plosone.org 10 August 2011 | Volume 6 | Issue 8 | e22924Figure 6. hBM-MSCs raised neural stem cell migration and SDF-1 secretion in QA-lesioned mice. (A–E) Confocal laser microscopic
observation of immunofluorescence labeled striatal sections after 8 weeks transplantation of hBM-MSCs into QA2lesioned mice. Transplanted hBM-
MSCs pre-labeled with bisbenzimide (A-b, B-c, C-c, D-b & E-b; blue) or co-labeled with TOTO3 (A-c & E-c; white) were immunostained for cell markers,
synaptophysin (A-a; green), laminin (B-a, C-a; green), Dcx (B-b; red), SDF-1 (C-b; red), VWF (D-a; red), and Cxcr4 (E-a; green). Corresponding merged
images are shown accordingly (A-d, B-d, C-d, D-c & E-d). Images A-e, B-e, C-e, D-d, and E-e were from the QA2lesioned group stained with the same
cell markers as A-d, B-d, C-d, D-c & E-d, respectively, except that bisbenzimide labeling was substituted with DAPI staining in D-d. Arrows indicate
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hBM-MSCs at the QA-lesioned striatum, while the second group
of mice received a unilateral injection of PBS at the corresponding
site. In 12-week-old R6/2-J2 mice, hBM-MSCs or PBS vehicle
was transplanted into the right hemisphere of the striatum. hBM-
MSCs were transplanted into two adjacent sites in the striatum
(,100,000 viable cells/ml; 2 ml per injection site) at the following
stereotaxic coordinates: site 1=AP 0 mm, ML 22.0 mm, and DV
23.0 mm DV, from the bregma; site 2=AP +1.0 mm, ML
22.0 mm, and DV 23.0 mm, from the bregma. The syringe was
left in place for 2 min before injection of cells over 5 min and was
retracted after an additional 5 min.
Rotarod Performance
An accelerating rotarod for mice (Model 47600, Ugo Basile) was
used to test motor performance in QA2lesioned mice, QA+-
transplant mice, hBM-MSC-transplant R6/2-J2 mice, PBS-
treated R6/2-J2 mice, and age and sex-matched sham-control
littermates. Twice a week during the experimental period, three
trials of 120 sec each at 30 r.p.m. for the QA mouse model and
16 r.p.m. for the R6/2-J2 mouse model were performed per day.
Bromodeoxyuridine Labeling
Bromodeoxyuridine (BrdU), a thymidine analogue which is
incorporated into the DNA of dividing cells during S-phase, was
used for mitotic labeling of proliferating cells (Sigma). The three
groups of mice in this study (QA2lesioned, QA+transplant, and
sham-control) received daily injections of BrdU (50 mg/kg i.p.) for
7 consecutive days before sacrificing.
Histologic analysis
Histologic analysis of mouse-brain volumes was performed as
previously described [70]. Continuous 50 mm coronal brain
sections from the striatum regions (bregma 1.54 to 0.10 mm) in
the neostriatum were used for volumetric analysis. The areas of the
striatum as determined by Nissl staining were calculated from each
continuous section and total volumes were measured by
integrating each section area and depth using Image-Pro Plus
6.0 software (Media Cybernetics, MD, USA).
Immunocytochemistry
Immunocytochemistry was performed to examine the charac-
teristics of the hBM-MSCs in the brains of mice that received
surgery. Mice were killed by an overdose of chloral hydrate,
perfused transcardially with chilled PBS and fixed with 4%
paraformaldehyde (pH 7.4 in PBS). Brains were removed,
postfixed overnight at 4uC, cryoprotected by immersion in 15%
sucrose solution for one day and transferred to 30% sucrose
solution for another day. Coronal sections (8 mm) were cryocut
through the striatum of frozen brains, mounted on poly-L-lysine
coated slides (Sigma), and stored at 220uC for immunocyto-
chemistry.
For BrdU immunostaining, DNA was first denatured by
incubating each brain section in 50% formamide in 26standard
saline citrate at 65uC for 2 h, immersed in 2 N HCl at 37uC for
30 min, and finally rinsed in 0.1 M boric acid (pH 8.5). Sections
were then rinsed with Tris buffer and incubated with 1% H2O2 to
block endogenous peroxidase. Immunostaining was performed
using the labeled streptavidin-biotin method (DAKO LASB-2 Kit,
Peroxidase, DAKO). Brain slides were incubated with the
appropriate diluted antibodies to BrdU (for nuclear identification,
1:400; Boehringer Mannheim) at room temperature for 1 h. The
slides were then washed with Tris-buffered saline containing 0.1%
Tween-20, and the specimens were sequentially incubated for 10–
30 min with biotinylated anti-rabbit (1:200; R&D Systems)
immunoglobulins and peroxidase-labeled streptavidin. Staining
was performed after 10 min incubation with a freshly prepared
substrate-chromogen solution and then counterstained with
hematoxylin. Brightfield images were taken using a digital camera
colocalization of cells and cell markers, yellow for both bisbenzimide and TOTO3 and pink for TOTO3 only. Scale bar=10 mm. Quantitation of laminin,
Dcx, and Cxcr4-positive cells (F) and percentage of SDF-1 (G) and VWF (H) expression areas in the hemispheres of striata from QA+transplant or
QA2lesioned groups. Error bars represent SD, and ** P,0.001, *** P,0.0001.
doi:10.1371/journal.pone.0022924.g006
Figure 7. Gene expression levels after transplantation were assessed by qRT-PCR. (A–B) Relative gene expression levels of SDF-1 and Cxcr4
in the brain tissues from QA (A) and R6/2-J2 (B) mice. The relative expression levels of genes were normalized with housekeeping genes; Cxcr4 was
normalized with Gapdh, and SDF-1 was normalized with GAPDH. Error bars represent SD, and * P,0.05, *** P,0.0001.
doi:10.1371/journal.pone.0022924.g007
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PLoS ONE | www.plosone.org 12 August 2011 | Volume 6 | Issue 8 | e22924Figure 8. hBM-MSCs reduced apoptosis in QA-lesioned mice. (A–D) Confocal laser microscopic observation of immunofluorescence labeled
striatal sections 8 weeks after hBM-MSC transplantation in QA-lesioned mice. Brain slides from the group with transplanted hBM-MSCs pre-labeled
with bisbenzimide (B-b & C-c; blue) or co-labeled with TOTO3 (A-b & C-d; white) and from the QA2lesioned group (A-d, B-d & D) were
immunostained for the cell markers caspase-3 (A-a; green), TUNEL (B-a; green), p-Erk1/2 (C-a & D-a; green), and Bax (C-b & D-b; red). Corresponding
merged images are shown accordingly (A-c, B-c & C-e). Images A-d, B-d, and D are from the QA2lesioned group, stained with the same cell markers
as A-c, B-c, and C, respectively, except that the bisbenzimide labeling was substituted with DAPI staining in B-d. Scale bar=10 mm. (E) Quantitation of
caspase-3, TUNEL, p-Erk1/2, and Bax-positive cells in the hemispheres of striata from QA+transplant or QA2lesioned groups. Error bars represent SD,
and * P,0.05, *** P,0.0001.
doi:10.1371/journal.pone.0022924.g008
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system (Diagnostic Instruments, Sterling Heights, MI).
Immunofluorescence was performed on mounted sections. After
rinsing briefly in PBS, slides were treated with 5% FBS in PBST
(PBS plus 0.2% Tween-20) for 30 min, all at room temperature,
and were then incubated with the primary antibody in PBST
overnight at 4uC. The antibodies used in this study include rabbit
anti-DARPP-32 (D32; 1:200; Chemicon), mouse anti-NeuN (1:50;
Chemicon), rabbit anti-GFAP (1:300; Chemicon), rat anti-F4/80
(1:50; Serotec), mouse anti-mitochondria (1:200; Millipore), goat
anti-doublecortin (Dcx; 1:50; Santa Cruz), mouse anti-synapto-
physin (1:200; Chemicon), rabbit anti-laminin (1:100; Sigma), goat
anti-SDF-1 (1:100; Santa Cruz), rabbit anti-VWF (1:100; DAKO),
rabbit anti-Cxcr4 (1:50; Torrey Pines Biolabs), rabbit anti-caspase-
3 (1:100; Cell Signaling), rabbit anti-p-Erk1/2 (1:100; Chemicon),
and mouse anti-Bax (1:100; BD). Sections were then rinsed three
times in PBST and incubated for a further hour with second
antibodies, including Alexa Fluor 488, 546, or 647-labeled donkey
anti-mouse, anti-rabbit, anti-rat, or anti-goat IgG (1:500; Invitro-
gen) antibodies, and Alexa Fluor 642-labeled TOTO-3 iodide dye
(1:1000; Invitrogen) or 49-6-Diamidino-2-phenylindole (DAPI;
1:1,000; Sigma) simultaneously to label the positions of cell nuclei.
Figure 9. Summary of possible mechanisms by which hBM-MSCs may alleviate cell damage. (A) Transplanted hBM-MSCs may
transdifferentiate into GFAP or neuronal cells. (B) The hBM-MSCs may secrete SDF-1 to induce the migration of host cells. (C) Cells near the
transplanted hBM-MSCs may undergo proliferation and differentiation to benefit the damaged striatal region.
doi:10.1371/journal.pone.0022924.g009
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scanning microscope (Carl Zeiss LSM510) equipped with UV,
argon, argon/krypton and helium/neon lasers.
TUNEL Assay
A TUNEL assay was performed to evaluate cell apoptosis after
hBM-MSC transplantation. After rehydration, slides were treated
with 20 mg/ml proteinase K for 8–10 min at room temperature,
washed with PBS, and re-fixed in 4% paraformaldehyde. Once
equilibrated, the slides were labeled for the fragmented DNA of
apoptotic cells using Nucleotide Mix and rTdT enzyme (DeadEnd
fluorometric TUNEL system, Promega,) at 37uC for 60 min and
the reaction stopped by incubation in 26SSC for 15 min. After
washing with deionized water, the slides were covered with glass
coverslips and analyzed under the fluorescence microscope.
Cell Counting
Cell counting was undertaken as described previously [62,71].
Cells were counted in three coronal sections covering the entire
striatum in three adjacent areas (AP 0 mm, AP +0.5 mm, and AP
+1.0 mm from bregma) close to the hBM-MSC transplantation
areas (AP 0 mm and AP +1.0 mm from bregma) in three
independent experiments under a microscope at 4006 magnifi-
cation. Unbiased stereological quantification of the total hemi-
spheric areas of each section was made with an image analysis
system (Image-Pro Plus 6.0, Media Cybernatics) to determine the
number and expression areas of the cells with positive signals.
RNA Extraction
Brain tissues were obtained from mice at different time-points,
and total RNA was extracted using Trizol reagent (Invitrogen).
About 100 mg of brain tissue was homogenized with 1 ml of
Trizol and 200 ml of chloroform and then shaken to mix. The
reaction was kept at room temperature for 5 min and spun for
15 min at 13,000 g at 4uC. The upper phase was then collected
and mixed with 500 ml of isopropanol to precipitate the RNA and
spun for 10 min at 12,000 rpm at 4uC. The RNA pellet was then
dissolved in 50 ml of diethyl pyrocarbonate (DEPC) -treated water
and quantified by spectrophotometer using a Narodrop (Biolab)
and kept for quantitative Real Time RT-PCR (qRT-PCR).
Quantitative real time RT-PCR Amplification
Quantitative real time RT-PCR (qRT-PCR) was performed
using SsoFast EvaGreen Supermix kit (Bio-Rad). Commercially
designed primers (Bio-Rad) for SDF-1 (NCBI: NM_000609) and
Cxcr4 (NCBI: NM_009911) were applied for gene expression
quantification; therefore, all primer sets possessed high genetic
specificity and produced a single dissociation and melting (Tm)
curve. Table 1 shows the sequences of primer sets used and the
annealing temperatures were all set at 55uC. One microgram of
total RNA isolated from brain tissues was used in a 20 ml cDNA
synthesis reaction using an iScript cDNA Synthesis kit (Bio-Rad).
One microliter of tenfold diluted cDNA sample was applied to the
PCR analysis within a total reaction volume of 20 ml. qRT-PCR
amplification was conducted with MiniOption System (Bio-Rad);
the thermal profile consisted of 30 sec at 98uC followed by 40
cycles of 2 sec at 98uC and 5 sec at 55uC, and then an additional
5 sec annealing step at 65uC. The relative quantification (ddCt)
data was normalized with the corresponding housekeeping genes,
Gapdh (NCBI: NM_008084) or GAPDH (NCBI: NM_002046), in
order to calculate the relative levels of gene expression by the
comparative method (Bio-Rad).
Statistical Analysis
All values shown in the figures are presented as mean 6 SD.
One-way ANOVA in combination with Bonferroni’s post-hoc
analysis were used to evaluate the Rotarod performance and
survival rates for unequal samples sizes. The numbers and the
expression areas of immunopositive cells, and the differences in
gene expression levels between groups measured by qRT-PCR
were analyzed by Student’s t-test for unpaired samples, using
Prism 4.0 (GraphPad software, CA, USA). A value of P,0.05 was
considered statistically significant.
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